Skip to content

Discontinued — last reported Q4 '23

Total Revenue at other companies

Pfizer logo
PfizerPFE
$14.45B+5.4%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$64.86M+224%
AbbVie logo
AbbVieABBV
$15B+12.4%
Immunome logo
ImmunomeIMNM
$0-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$17M-39.3%
Incyte logo
IncyteINCY
$1.27B+20.9%

Other financials

Income statement

See full
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: SELLAS Life Sciences Group, Inc.’s 10-K, filed March 28, 2024, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s total revenue?
SELLAS Life Sciences Group, Inc. (SLS) reported total revenue of $0 in Q4 2023.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s total revenue?
Over 2 years (2021 to 2023), SELLAS Life Sciences Group, Inc.'s total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $7.6M to $0.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.